Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment

@article{Goodkin2011CerebrospinalAP,
  title={Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment},
  author={K. Goodkin and B. Vitiello and W. Lyman and D. Asthana and J. Atkinson and P. Heseltine and Rebeca Molina and Wenli Zheng and I. Khamis and F. Wilkie and P. Shapshak},
  journal={Journal of NeuroVirology},
  year={2011},
  volume={12},
  pages={178-189}
}
Abstractd-Ala1-peptide T-amide (DAPTA) has shown neuroprotection in vitro against gp120-induced loss of dendritic arborization and is promulgated as a CCR5 antagonist. A multisite, randomized, double-blind clinical trial of DAPTA versus placebo prior to combination antiretroviral therapy conducted with human immunodeficiency virus (HIV)-1 seropositive participants having cognitive impairment showed no overall cognitive effect, though subgroups with greater impairment and CD4 cell counts of 201… Expand
HIV-1-Associated Neurocognitive Disorders in the HAART Era
TLDR
Changes have occurred across the spectrum of HIV-1-associated neurocognitive disorders since the introduction of HAART, and both the neuropathological and the clinical aspects of the syndrome seem to be less severe than those observed in the pre-HAART era. Expand
Adjuvant therapies for HIV-associated neurocognitive disorders
TLDR
It is discussed that study results may also be influenced by clinical trial design, and this lack of efficacy may be because the appropriate therapeutic targets have not yet been determined. Expand
The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model.
TLDR
The results suggest that B18R crosses the BBB, blocks IFN-α signaling, and it prevents key features of HIVE pathology, a viable alternative to monoclonal antibodies for the inhibition of IFn-α in the immune-suppressed environment. Expand
New classes of anti-HIV-1 compounds active at different stages of infection
TLDR
Two CCR5 inhibitors, DAPTA and TAK-779, are potent anti-HIV-1 compounds able to block the virus entry of R5 HIV-1 strains in M/M, suppressing viral replication in the cells and contributing to a possible synergism with other antiretroviral treatments. Expand
Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS1
TLDR
It is concluded that nanoART targeting to diseased brain through macrophage carriage is possible and can be considered in developmental therapeutics for HIV-associated neurological disease. Expand
Virobiome Derived Peptide T: Anti-Inflammatory Peptides for Treating Neuro-Aids and Neurodegenerative Diseases
The identification of biologically significant, receptor-targeting epitopes from the “virobiome”, the diverse population of viruses which engage the host immune system, especially those determinantsExpand
Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review).
TLDR
This study reviewed articles, clinical trials, and conference communications about all the drugs under investigation belonging to the class of entry and fusion inhibitors that are at least in phase I clinical trials. Expand
19 Pathogenesis and Treatment of HIV-associated Dementia: Recent Studies in a SCID Mouse Model
TLDR
An overview of HIV-Associated Dementia is provided for the first time in a systematic review of current literature on the subject. Expand

References

SHOWING 1-10 OF 52 REFERENCES
Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
TLDR
Peptide T treatment was associated with overall cognitive improvement in patients with baseline global deficit scores of at least 0.5, while overall deterioration was more common among the placebo group, and analyses suggested a greater improvement in the peptide T group. Expand
Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients
TLDR
A negative interaction between virological response and the duration of antiretroviral treatment suggests long-term selection of drug-resistant CSF HIV-1 strains. Expand
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection.
TLDR
In HIV-1-infected patients with neurologic complications, no significant correlations were found between immune activation, CSF viral load, and immunosuppression. Expand
Can the peripheral blood monocyte count be used as a marker of CSF resistance to antiretroviral drugs?
TLDR
Preliminary data suggest that peripheral blood monocytes may be important in delivery of antiretroviral drugs to the brain and the development of resistance. Expand
Can the peripheral blood monocyte count be used as a marker of CSF resistance to antiretroviral drugs
TLDR
It is suggested that peripheral blood monocytes may be important in delivery of antiretroviral drugs to the brain and the development of resistance, and a significant decline in the concentration of each drug in the supernatant implied that it had been "taken up" by the monocytes. Expand
Elevated expression of IFN-gamma in the HIV-1 infected brain.
We determined the extent of expression of three cytokines (IFN-gamma, IL-4, and TNF-alpha ) in brain tissue infected with human immunodeficiency virus-1 (HIV-1). The selections were IFN-gamma as aExpand
HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates
TLDR
Co-treatment with peptide T, a gp120-derived peptide having a pentapeptide sequence homologous with vasoactive intestinal peptide, prevented or attenuated the morphological damage and behavioral delays associated with gp120 treatment. Expand
Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5).
TLDR
Results show that peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4, explaining past inconsistencies of in vitro antiviral effects. Expand
CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing
TLDR
Multiple and single CSF-penetrating HAART may be equivalent for treating HIV-associated psychomotor slowing and there were no differences in the mean change for CD4 count, viral load, or any of the neuropsychological tests. Expand
VIP and d-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death
TLDR
These studies suggest that the neuroprotective action of VIP is linked in part to its release of MIP-1alpha, and neuroprotection produced by chemokines is dependent on both the type of chemokine and the variant structure of gp120 and may be relevant to drug strategies for the treatment of AIDS dementia. Expand
...
1
2
3
4
5
...